Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $24.00 at BTIG Research

Zevra Therapeutics (NASDAQ:ZVRA) had its price target decreased by BTIG Research from $27.00 to $24.00 in a research note issued to investors on Monday, Marketbeat.com reports. BTIG Research currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on the company. Weiss Ratings lowered Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Cantor Fitzgerald boosted their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Maxim Group upped their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, June 9th. Finally, UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.86.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $9.71 on Monday. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $15.03. The firm has a market cap of $574.06 million, a P/E ratio of 4.88 and a beta of 0.85. The firm’s 50-day simple moving average is $12.36 and its 200 day simple moving average is $10.49.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. As a group, equities analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Stratos Wealth Partners LTD. raised its holdings in Zevra Therapeutics by 78.6% in the 4th quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock valued at $3,665,000 after acquiring an additional 180,000 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Zevra Therapeutics by 1,458.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 438,984 shares of the company’s stock worth $4,175,000 after purchasing an additional 410,823 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Zevra Therapeutics during the 1st quarter worth $11,184,000. Hennion & Walsh Asset Management Inc. bought a new position in shares of Zevra Therapeutics in the fourth quarter worth $1,251,000. Finally, UBS Group AG increased its position in shares of Zevra Therapeutics by 30.9% in the fourth quarter. UBS Group AG now owns 285,488 shares of the company’s stock worth $2,558,000 after purchasing an additional 67,392 shares during the period. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.